Comparison of Immune Response to Booster Vaccines in Blood Transplant Patients and Healthy Volunteers
Evaluation of Hepatitis B Surface Antigen-Specific and Tetanus Toxoid-Specific Lymphocytes
This study will compare the immune system response to booster vaccines for tetanus/diphtheria and hepatitis B in healthy volunteers with that of patients who have had a blood transplant. (A blood transplant is an infusion of donated stem cells-i.e., cells that mature into white blood cells, red blood cells and platelets). The study will also look at how age of the blood cell donor and recipient, the type of blood transplant, the amount of certain types of white cells in donor blood, and other variables may influence the vaccine response among the transplant patients.
This study includes normal volunteers and patients who have had a blood transplant. Healthy volunteers between the ages of 18 and 60 who have previously been vaccinated with the hepatitis B or tetanus/diphtheria vaccine and have not had hepatitis B may be eligible for this study. Patients enrolled in a blood cell transplant study at NIH who are between 5 and 60 years old, have been vaccinated against tetanus/diphtheria, and have not had hepatitis B may be eligible. Candidates will be screened with a medical history and blood tests.
Those enrolled in the study will have about 2 tablespoons of blood drawn before vaccination with a standard tetanus/diphtheria booster shot. Volunteers who have previously been vaccinated with the hepatitis B vaccine and all blood transplant patients will also receive a hepatitis B vaccination. Participants will have blood drawn (from 1 to 5 tablespoons) up to once a week after vaccination for no more than 8 weeks to evaluate the immune response to vaccination.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Type d'étude
Inscription
Contacts et emplacements
Lieux d'étude
-
-
Maryland
-
Bethesda, Maryland, États-Unis, 20892
- National Institute of Allergy and Infectious Diseases (NIAID)
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
HEALTHY VOLUNTEERS:
Male or female subjects who are at least 18 years of age, but no older than 60 years of age.
Received complete hepatitis B and/or tetanus/diphtheria vaccination series.
If female, have a negative urine or serum pregnancy test within two weeks prior to entry into this study, and agree to avoid pregnancy during entire participation through the use of effective birth control or abstinence.
Volunteers reporting good general health and denying any illness that can adversely affect an immune response to a vaccine.
No history of a serious adverse event associated with any previous vaccination.
Not participating in another experimental vaccine study.
Serum hemoglobin greater than or equal to 11 g/dL.
No history of hepatitis B.
Must not have received a tetanus/diphtheria or hepatitis B booster in the last 6 months.
HSCT VOLUNTEERS:
Male or female subjects who are at least 5 years of age, but no older than 60 years of age.
Be enrolled in a HSCT protocol at NIH.
Be greater than or equal to 3 months post-HSCT.
Received tetanus/diphtheria vaccination series.
If female, have a negative urine or serum pregnancy test within two weeks prior to entry into this study, and agree to avoid pregnancy during entire participation through the use of effective birth control or abstinence.
No history of a serious adverse event associated with any previous vaccination.
Not participating in another experimental vaccine study.
Serum hemoglobin greater than or equal to 9 g/dL.
No history of hepatitis B.
Not receiving any more than replacement glucocorticoid therapy.
Not receiving any dose of cyclosporine.
No acute graft-versus-host disease grade II or higher, at time of consideration for study.
No chronic graft-versus-host disease more involved than localized skin lesions and/or liver dysfunction, at time of consideration for study.
Must not have received a tetanus/diphtheria or hepatitis B booster in the last 6 months.
Plan d'étude
Comment l'étude est-elle conçue ?
Collaborateurs et enquêteurs
Publications et liens utiles
Publications générales
- Li Volti S, Mauro L, Di Gregorio F, Romeo MA, Lupo L, Pizzarelli G, Mangiagli A, Giammanco G, Russo G. Immune status and immune response to diphtheria-tetanus and polio vaccines in allogeneic bone marrow-transplanted thalassemic patients. Bone Marrow Transplant. 1994 Aug;14(2):225-7.
- Ljungman P, Cordonnier C, de Bock R, Einsele H, Engelhard D, Grundy J, Link H, Locasciulli A, Prentice G, Reusser P, et al. Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1995 Mar;15(3):455-60.
- Singhal S, Mehta J. Reimmunization after blood or marrow stem cell transplantation. Bone Marrow Transplant. 1999 Apr;23(7):637-46. doi: 10.1038/sj.bmt.1701640.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 000144
- 00-I-0144
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur En bonne santé
-
AstraZenecaParexelComplété